Leukemia Research
Volume 26, Issue 3 , Pages 221-228 , March 2002

Runx1/AML1 in leukemia: disrupted association with diverse protein partners

  • Chava Perry

      Affiliations

    • Department of Biological Chemistry, The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
    • Department of Hematology, Sackler Faculty of Medicine, Tel Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv 64239, Israel
    • ,
  • Amiram Eldor

      Affiliations

    • Department of Hematology, Sackler Faculty of Medicine, Tel Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv 64239, Israel
    • ,
  • Hermona Soreq

      Affiliations

    • Department of Biological Chemistry, The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-2-658-5109; fax: +972-2-652-0258

Received 11 July 2001 ,Accepted 11 July 2001.

References 

  1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J. Clin. 1997;47:5–27
  2. Pierce MI, Borges WH, Heyn R, Wolff JA, Gilbert ES. Epidemiological factors and survival experience in 1770 children with acute leukemia. Treated by members of Children's Study Group A between 1957 and 1964. Cancer. 1969;23:1296–1304
  3. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene. 2000;245:223–235
  4. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics. 1994;23:425–432
  5. Westendorf JJ, Hiebert SW. Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia, J Cell Biochem 1999(Suppl)51–8.
  6. Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, Satake M, et al.  PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc. Natl. Acad. Sci. USA. 1993;90:6859–6863
  7. Nagata T, Gupta V, Sorce D, Kim WY, Sali A, Chait BT, et al.  Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. Nat. Struct. Biol. 1999;6:615–619
  8. Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, et al.  Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res. 1995;23:2762–2769
  9. Tanaka T, Tanaka K, Ogawa S, Kurokawa M, Mitani K, Yazaki Y, et al.  An acute myeloid leukemia gene, AML1, regulates transcriptional activation and hemopoietic myeloid cell differentiation antagonistically by two alternative spliced forms. Leukemia. 1997;11(Suppl 3):299–302
  10. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321–330
  11. Namba K, Abe M, Saito S, Satake M, Ohmoto T, Watanabe T, et al.  Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity of a murine endothelial cell MSS31. Oncogene. 2000;19:106–114
  12. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA. 1996;93:3444–3449
  13. Hernandez-Munain C, Krangel MS. Regulation of the T-cell receptor delta enhancer by functional cooperation between c-Myb and core-binding factors. Mol. Cell Biol. 1994;14:473–483
  14. Sun W, Graves BJ, Speck NA. Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins. J. Virol. 1995;69:4941–4949
  15. Zhang DE, Hetherington CJ, Meyers S, Rhoades KL, Larson CJ, Chen HM, et al.  CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol. Cell Biol. 1996;16:1231–1240
  16. Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang DE. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol. Cell Biol. 1998;18:3915–3925
  17. Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol. Cell Biol. 1998;18:322–333
  18. Redondo JM, Pfohl JL, Hernandez-Munain C, Wang S, Speck NA, Krangel MS. Indistinguishable nuclear factor binding to functional core sites of the T-cell receptor delta and murine leukemia virus enhancers. Mol. Cell Biol. 1992;12:4817–4823
  19. Lenny N, Westendorf JJ, Hiebert SW. Transcriptional regulation during myelopoiesis. Mol. Biol. Rep. 1997;24:157–168
  20. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 1998;17:2994–3004
  21. Bruhn L, Munnerlyn A, Grosschedl R. ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function. Genes Dev. 1997;11:640–653
  22. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 1999;18:2551–2562
  23. Blobel GA. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood. 2000;95:745–755
  24. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059–1064
  25. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 2001;20:723–733
  26. Uchida H, Zhang J, Nimer SD. AML1A and AML1B can transactivate the human IL-3 promoter. J. Immunol. 1997;158:2251–2258
  27. Hohaus S, Petrovick MS, Voso MT, Sun Z, Zhang DE, Tenen DG. PU.l (Spi-1) and C/EBP alpha regulate expression of the granulocyte–macrophage colony-stimulating factor receptor alpha gene. Mol. Cell Biol. 1995;15:5830–5835
  28. Zhang DE, Fujioka K, Hetherington CJ, Shapiro LH, Chen HM, Look AT, et al.  Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol. Cell Biol. 1994;14:8085–8095
  29. Suzow J, Friedman AD. The murine myeloperoxidase promoter contains several functional elements, one of which binds a cell type-restricted transcription factor, myeloid nuclear factor 1 (MyNF1). Mol. Cell Biol. 1993;13:2141–2151
  30. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol. Cell Biol. 1994;14:5558–5568
  31. Wargnier A, Legros-Maida S, Bosselut R, Bourge JF, Lafaurie C, Ghysdael CJ, et al.  Identification of human granzyme B promoter regulatory elements interacting with activated T-cell-specific proteins: implication of Ikaros and CBF binding sites in promoter activation. Proc. Natl. Acad. Sci. USA. 1995;92:6930–6934
  32. Erman B, Cortes M, Nikolajczyk BS, Speck NA, Sen R. ETS-core binding factor: a common composite motif in antigen receptor gene enhancers. Mol. Cell Biol. 1998;18:1322–1330
  33. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 1976;33:451–458
  34. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817–1824
  35. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL, et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000;96:2862–2869
  36. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol. Cell Biol. 1995;15:1974–1982
  37. Aronson BD, Fisher AL, Blechman K, Caudy M, Gergen JP. Groucho-dependent and -independent repression activities of Runt domain proteins. Mol. Cell Biol. 1997;17:5581–5587
  38. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293
  39. Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. Hematology basic principles and practice. 3rd ed. London: Churchill Livingstone; 2000;
  40. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood. 1995;86:1–14
  41. Erickson PF, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin HA. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood. 1996;88:1813–1823
  42. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell Biol. 1998;18:7185–7191
  43. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, et al.  ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell Biol. 1998;18:7176–7184
  44. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000;19:1745–1754
  45. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J, et al.  Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J. Biol. Chem. 2000;275:40282–40287
  46. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc. Natl. Acad. Sci. USA. 1996;93:14059–14064
  47. Samuels BL, Larson RA, Le Beau MM, Daly KM, Bitter MA, Vardiman JW, et al.  Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia. 1988;2:79–83
  48. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179
  49. Lutterbach B, Sun D, Schuetz J, Hiebert SW. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol. Cell Biol. 1998;18:3604–3611
  50. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712–715
  51. Okuda T, Cai Z, Yang S, Lenny N, Lyn CJ, van Deursen JM, et al.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91:3134–3143
  52. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ, et al.  Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000;96:2108–2115
  53. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985–1989
  54. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffe M, Jonveaux P, et al.  High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 1995;86:4263–4269
  55. Rubnitz JE, Downing JR, Pui CH, Shurtleff SA, Raimondi SC, Evans WE, et al.  TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J. Clin. Oncol. 1997;15:1150–1157
  56. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, et al.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA. 1995;92:4917–4921
  57. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, et al.  The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol. Cell Biol. 1996;16:1349–1355
  58. Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene. 1999;18:1015–1022
  59. Stegmaier K, Pendse S, Barker GF, Bray-Ward P, Ward DC, Montgomery KT, et al.  Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. Blood. 1995;86:38–44
  60. Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowley JD. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER1. Proc. Natl. Acad. Sci. USA. 1993;90:7784–7788
  61. Zent C, Rowley JD, Nucifora G. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies. Leukemia. 1997;11(Suppl 3):273–278
  62. Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, Hirai H. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J. Biol. Chem. 1994;269:24020–24026
  63. Sacchi N, Nisson PE, Watkins PC, Faustinella F, Wijsman J, Hagemeijer A. AML1 fusion transcripts in t(3;21) positive leukemia: evidence of molecular heterogeneity and usage of splicing sites frequently involved in the generation of normal AML1 transcripts. Genes Chromosomes Cancer. 1994;11:226–236
  64. Gnatt A, Ginzberg D, Lieman Hurwitz J, Zamir R, Zakut H, Soreq H. Human acetylcholinesterase and butyrylcholinesterase are encoded by two distinct genes. Cell Mol. Neurobiol. 1991;11:91–104
  65. Allderdice PW, Gardner HA, Galutira D, Lockridge O, LaDu BN, McAlpine PJ. The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics. 1991;11:452–454
  66. Blair A. Herbicides and non-Hodgkin's lymphoma: new evidence from a study of Saskatchewan farmers. J. Natl. Cancer Inst. 1990;82:544–545
  67. Clavel J, Hemon D, Mandereau L, Delemotte B, Severin F, Flandrin G. Farming, pesticide use and hairy-cell leukemia. Scand. J. Work Environ. Health. 1996;22:285–293
  68. Richardson S, Zittoun R, Bastuji-Garin S, Lasserre V, Guihenneuc C, Cadiou M, et al.  Occupational risk factors for acute leukaemia: a case-control study. Int. J. Epidemiol. 1992;21:1063–1073
  69. Brown LM, Blair A, Gibson R, Everett GD, Cantor KP, Schuman LM, et al  Pesticide exposure and other agricultural risk factors for leukemia among men in Iowa and Minnesota. Cancer Res. 1990;50:6585–6591
  70. Loewenstein Lichtenstein Y, Schwarz M, Glick D, Norgaard Pedersen B, Zakut H, Soreq H. Genetic predisposition to adverse consequences of anti-cholinesterases in ‘atypical’ BCHE carriers. Nat. Med. 1995;1:1082–1085
  71. Prody CA, Dreyfus P, Zamir R, Zakut H, Soreq H. De novo amplification within a ‘silent’ human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides. Proc. Natl. Acad. Sci. USA. 1989;86:690–694
  72. Lapidot-Lifson Y, Prody CA, Ginzberg D, Meytes D, Zakut H, Soreq H. Coamplification of human acetylcholinesterase and butyrylcholinesterase genes in blood cells: correlation with various leukemias and abnormal megakaryocytopoiesis. Proc. Natl. Acad. Sci. USA. 1989;86:4715–4719
  73. Robitzki A, Mack A, Hoppe U, Chatonnet A, Layer PG. Butyrylcholinesterase antisense transfection increases apoptosis in differentiating retinal reaggregates of the chick embryo. J. Neurochem. 1998;71:413–420
  74. Willbold E, Layer PG. Butyrylcholinesterase regulates laminar retinogenesis of the chick embryo in vitro. Fur. J. Cell Biol. 1994;64:192–199
  75. Kere J, Ruutu T, de la Chapelle A. Monosomy 7 in granulocytes and monocytes in myelodysplastic syndrome. N. Engl. J. Med. 1987;316:499–503
  76. Le Beau MM, Espinosa R, Davis EM, Fisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996;88:1930–1935
  77. Zenklusen JC, Weitzel JN, Ball HG, Conti CJ. Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogene. 1995;11:359–363
  78. Zenklusen JC, Hodges LC, LaCava M, Green ED, Conti CJ. Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site. Oncogene. 2000;19:1729–1733
  79. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, et al.  Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk. Res. 1987;11:119–133
  80. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood. 1998;92:2322–2333
  81. Hoff PM, Pierce S, Estey E. Comparison of acute myeloid leukemia patients at MD Anderson: 1982–1986 vs 1992–1996. Leukemia. 1997;11:1997–1998
  82. Johnson E, Cotter FE. Monosomy 7 and 7q-associated with myeloid malignancy. Blood Rev. 1997;11:46–55
  83. Ehrlich G, Viegas Pequignot E, Ginzberg D, Sindel L, Soreq H, Zakut H. Mapping the human acetylcholinesterase gene to chromosome 7q22 by fluorescent in situ hybridization coupled with selective PCR amplification from a somatic hybrid cell panel and chromosome-sorted DNA libraries. Genomics. 1992;13:1192–1197
  84. Getman DK, Eubanks JH, Camp S, Evans GA, Taylor P. The human gene encoding acetylcholinesterase is located on the long arm of chromosome 7. Am. J. Hum. Genet. 1992;51:170–177
  85. Stephenson J, Czepulkowski B, Hirst W, Mufti G. Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Leuk. Res. 1996;20:235–241
  86. Patinkin D, Lev Lehman E, Zakut H, Eckstein F, Soreq H. Antisense inhibition of butyrylcholinesterase gene expression predicts adverse hematopoietic consequences to cholinesterase inhibitors. Cell Mol. Neurobiol. 1994;14:459–473
  87. Paulus JM, Maigne J, Keyhani E. Mouse megakaryocytes secrete acetylcholinesterase. Blood. 1981;58:1100–1106
  88. Soreq H, Patinkin D, Lev-Lehman E, Grifman M, Ginzberg D, Eckstein F, et al.  Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis ex vivo. Proc. Natl. Acad. Sci. USA. 1994;91:7907–7911
  89. Lev-Lehman E, Deutsch V, Eldor A, Soreq H. Immature human megakaryocytes produce nuclear-associated acetylcholinesterase. Blood. 1997;89:3644–3653
  90. Grisaru D, Deutch V, Shapira M, Pick M, Sternfeld M, Melamed-Book N, et al.  ARP, a peptide derived from the stress-associated acetylcholinesterase variant has hematopoietic growth promoting activities. Mol. Med. 2001;7:93–105
  91. Razon N, Soreq H, Roth E, Bartal A, Silman I. Characterization of levels and forms of cholinesterases in human primary brain tumors. Exp. Neurol. 1984;84:681–695
  92. Gurwitz D, Razon N, Sokolovsky M, Soreq H. Expression of muscarinic binding sites in primary human brain tumors. Brain Res. 1984;316:61–70
  93. Karpel R, Sternfeld M, Ginzberg D, Guhl E, Graessmann A, Soreq H. Overexpression of alternative human acetylcholinesterase forms modulates process extensions in cultured glioma cells. J. Neurochem. 1996;66:114–123
  94. Koenigsberger C, Chiappa S, Brimijoin S. Neurite differentiation is modulated in neuroblastoma cells engineered for altered acetylcholinesterase expression. J. Neurochem. 1997;69(4):1389–1397
  95. Grisaru D, Lev-Lehman E, Shapira M, Chaikin E, Lessing JB, Eldor A, et al.  Human osteogenesis involves differentiation-dependent increases in the morphogenically active 3′ alternative splicing variant of acetylcholinesterase. Mol. Cell Biol. 1999;19:788–795
  96. Grifman M, Soreq H. Differentiation intensifies the susceptibility of pheochromocytoma cells to antisense oligodeoxynucleotide-dependent suppression of acetylcholinesterase activity. Antisense Nucleic Acid Drug Dev. 1997;7:351–359
  97. Soreq H, Seidman S. Acetylcholinesterase—new roles for an old actor. Nat. Rev. Neurosci. 2001;2:294–302
  98. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J. Biol. Chem. 2000;275:651–656
  99. Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, et al.  Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 1994;13:504–510

PII: S0145-2126(01)00128-X

Leukemia Research
Volume 26, Issue 3 , Pages 221-228 , March 2002

Article Tools

* Image Usage & Resolution